新华社武汉7月13日电（记者乐文婉）盛夏时节，凌晨三点，万籁俱寂。在湖北省潜江市杨市街道李滩村，二组村民丁元凯换好连体防水服，打着 手电筒、撑起小船驶入虾塘，开始了一天的劳作。泛着微光的水面上，一只只张牙舞爪的红色小龙虾正从笼中探头而出。 等到60亩虾田巡塘完毕，天色微亮，塘边已有虾贩等候多时。"天气一热，小龙虾就爱钻洞避暑，这几天出塘量有所减少。前几个月凉快的时候， 我一天最多能起大几百斤虾。"丁元凯说，"但不论冷暖，捕多少就能卖多少，潜江小龙虾声名在外，不愁销路。" 今年是丁元凯从事小龙虾养殖的第九个年头。目前，他拥有50亩虾稻共作田和10亩精养塘，规模逐年扩大。"去年我的亩均收益超过5000元，今年 小龙虾饲料每吨便宜了500元，加上产量提升、行情上涨，今年效益肯定比去年好。" 丁元凯并非个例。数据显示，今年上半年，潜江规格2至4钱的小青龙虾均价为18.9元/斤、规格4至6钱的中青为26.5元/斤，分别同比上涨16.7%和 8.2%。唯一出现回落的是规格8.8钱以上的"炮头"，今年1至5月的均价为73.6元/斤，同比下降9.1%。 在全国多地小龙虾价格普遍回落、甚至"腰斩"的背景下，潜江小龙虾为何能够逆 ...

每当看到新鲜葡萄渗出酒味，或是芒果表皮浮现黑斑，我们都在见证一场微观世界的"真菌入侵"。 这些看似普通的腐败现象背后，是灰葡萄孢霉、酿酒酵母和胶孢炭疽菌等真菌的"杰作"。它们通过分泌胞外酶破坏水果表皮，消耗水果营养物 质，劣化感官品质甚至产生毒素，每年在全球范围内造成价值千亿元的农产品损失，这个数字足以让每个水果爱好者扼腕。 "要是水果的新鲜期再长一点就好了……""怎么才能延长水果的保质期呢？"你是否也有过这样的想法？针对这一需求，中国科学院成都生物研究 所微生物源农药与制剂研发创新团队的科学家们已经找到了高效、安全、无污染的解决方案！ 大自然的"抗菌战士"——伊枯草菌素 A 过去，为了让水果"活"得久一点，果农和商家常喷洒化学杀菌剂使其保鲜。这些药剂虽然能暂时赶走真菌，但也存在问题：化学残留可能危害人 体健康，长期使用还会污染环境。随着消费者对"零农残"需求的增长，科学家将目光转向了自然界本身——那些与真菌搏斗了亿万年的微生物拮 抗系统。 在自然界中，潜藏着一支特殊的"抗菌特工队"——伊枯草菌素 A（Iturin A，简称 IA），它是由土壤中某些芽孢杆菌分泌的脂肽化合物。这种由氨 基酸和脂肪酸构成的环状分 ...

投资建议：产品端单品突破仍存机遇，新品中重点关注肉毒/再生/PDRN等品类进展，运营上看好头部 企业持续领先 据德勤预测，2023年我国医美终端规模逾2300亿元，预计24~27CAGR+10%~+15%;其中注射类规模占比 约1/4，预计未来5年规模CAGR+20%~+30%。短期，受宏观经济增长降速与基数影响，部分医美企业业 绩阶段性承压、表现分化。展望未来，该行测算每千人医美诊疗次数韩国/日本/中国分别为91次 (2019)/71次(2023E)/34次(2023E)，未来认知度提升与客群老龄化有望带来较大空间;同时注射类产品受 益于丰富的品类供给和消费者认可，有望在轻医美潮流中获得较行业整体更快的增速。 发展趋势：产品竞争格局或将U型演变，头部企业有望依靠运营能力保持优势 ①产品维度，短期单品获批周期长带来新证稀缺性，中长期集中度料"U"型演变：医美产品作为医疗器 械/药品，审批时间长，品类早期受制于牌照稀缺、集中度高;中期竞争对手增加使格局分散，但最终企 业经营能力分化，料将推动集中度再次提升。 ①产品端：非透明质酸材料批文数量有限，产品端单品突破存机遇。据动脉网统计，我国已获批医美注 射针剂批文超 ...

Core Viewpoint - The company has approved a comprehensive credit facility of up to 2 billion RMB to support its subsidiary, Fujian Huakang Pharmaceutical Co., Ltd, through various banks and financial institutions [1][2]. Group 1: Guarantee Details - The company has provided a total guarantee amount of 15 million RMB, leaving a remaining guarantee capacity of 65 million RMB as of the announcement date [2][4]. - Fujian Huakang is a wholly-owned subsidiary of the company, with the company holding 85% of its shares [3][4]. - The guarantee is aimed at meeting the operational needs of the subsidiary and is deemed to have low risk due to the company's control over the subsidiary [4]. Group 2: Financial Information - As of December 31, 2024, Fujian Huakang reported total assets of 58.23 million RMB, total liabilities of 34.01 million RMB, and net assets of 24.23 million RMB [2]. - As of March 31, 2025, Fujian Huakang's total assets increased to 61.10 million RMB, with total liabilities of 30.74 million RMB and net assets of 30.36 million RMB [3]. Group 3: Guarantee Agreement - The company signed a maximum guarantee contract with Xiamen Bank for a guarantee amount of 15 million RMB for Fujian Huakang [3][4]. - There are no associated guarantees or overdue guarantees reported [3][4].

2025山东省外贸优品购物季第四期工艺品、礼品、装饰品类外贸优品购物节将于6月13日至17日在山东国际会展中心5号馆盛大举行。作为 聚焦"外贸优品"的内销主题展会，活动将汇聚全省近300家工艺品、礼品、装饰品等领域的优质外贸企业，并吸引超2000家专业采购商到 场。通过搭建供需精准对接平台，助力山东外贸优品开拓国内市场，实现促消费与稳外贸同频共振。 活动现场，将重磅发布"内外贸融合行动"并签署《山东外贸优品全国市场融合发展备忘录》，此外，还将率先启动"老字号+外贸优品"供 应链共建行动，为中国品牌的高质量发展注入强劲动能。 展区重点打造中国(山东)自由贸易试验区济南片区国家文化出口基地展区、博山陶琉国家文化出口基地展区、草柳手作展区、礼品、工艺 品展区、装饰品展区。全方位呈现山东工艺品行业的外贸优品魅力。展区行业领军品牌强势集结，从海洋生物中提取壳聚糖，把玉米秸秆 农业废料变成可纺纤维；用虾蟹壳开发功能性材料的高新技术企业青岛即发。淄博琉璃工艺品的代表精工美琉，荣华文创、特色礼品翘楚 阿尔发与创意葫芦代表春啼鸟、木雕大师周广胜与匠心品牌木头记、钟表领先者康巴丝及品质家居齐家家居等将携国际标准优品集体亮 相，充 ...

马卓 ◎记者 李少鹏 在全球经济格局深度调整、产业转型加速升级的背景下，炭素行业正站在新旧动能转换的"十字路口"。 面对行业下行压力，如何在变局中破浪前行、如何通过技术创新开辟新赛道，成为方大炭素董事长马卓 重点思考的问题。 "我们不能坐等行业回暖，在下行周期内，更要勤修'内功'，优化提升资源配置效率，保持领先地 位。"在马卓看来，唯有通过成本控制、精细化管理等举措，努力提升产品质量，才能筑牢核心竞争 力。 挑战就是机遇，变革带来希望。除了稳固石墨电极"老本行"外，马卓认为，公司还需深耕科技创新沃 土，持续加强人才队伍建设，在炭/炭复合材料、石墨烯等新赛道寻求更多突破，多措并举筑牢高质量 发展"底座"，进一步夯实炭素行业龙头企业的优势地位。 聚焦炭素主业 在变局中巩固行业地位 面对行业周期性波动带来的不利影响，马卓并没有回避。他告诉记者，受上游原材料价格持续波动、下 游钢铁行业市场需求缩减以及错综复杂的国际经济形势等因素影响，近几年石墨电极产品价格持续低位 运行，公司盈利水平有所下降。 "越是行业调整期，越要回归主业的本质价值。"尽管行业下行带来诸多挑战，但马卓认为若想锻造穿越 周期的能力，还需要苦练"内功" ...

Financial Performance - In 2024, the company achieved a revenue of CNY 41.906 billion, a year-on-year increase of 3.16% [4] - The net profit attributable to shareholders was CNY 3.512 billion, up 23.72% year-on-year [4] - The net profit after deducting non-recurring gains and losses was CNY 3.352 billion, reflecting a growth of 22.48% [4] - Compared to 2021, revenue and net profit grew by 21.24% and 52.59%, respectively [4] Business Segments Performance Pharmaceutical Industry - The pharmaceutical segment generated a revenue of CNY 13.811 billion, with a year-on-year growth of 13.05% [5] - The net profit for this segment was CNY 2.876 billion, increasing by 29.04% [5] - R&D investment in the pharmaceutical industry reached CNY 2.678 billion, a 16.77% increase [5] Aesthetic Medicine - The domestic aesthetic medicine subsidiary reported a revenue of CNY 1.139 billion, growing by 8.32% [6] - The UK subsidiary, Sinclair, generated approximately CNY 0.967 billion, a decline of 25.81% due to global economic challenges [6] Industrial Microbiology - The industrial microbiology segment achieved a revenue of CNY 0.711 billion, a significant increase of 43.12% [25] - Growth rates for specific areas included 38% for specialty raw materials and intermediates, 20% for xRNA, and 142% for health and biological materials [25] R&D and Product Development - The company has over 80 innovative drug candidates in its pipeline [5] - The oral small molecule GLP-1 receptor agonist HDM1002 has shown promising results in clinical trials, with over 800 participants [17] - The ADC pipeline includes more than 12 projects, with ongoing clinical trials for several candidates [14] Market Strategy and Future Outlook - The company plans to actively participate in medical insurance negotiations for new products [6] - There is a focus on expanding market presence in both domestic and international markets, particularly in the aesthetic medicine sector [26] - The company anticipates a gradual recovery in overseas aesthetic medicine markets [26] Investor Relations and Communication - The annual performance meeting was attended by 381 institutional and individual investors [2] - The chairman emphasized the commitment to high-quality development and strategic goals for the upcoming three-year plan [27]